Alopecia Areata Drugs: Comparative Efficacy Analysis
New Network Meta-Analysis Offers insights into Alopecia Areata Treatment Efficacy
Table of Contents
A recent network meta-analysis has shed light on the comparative effectiveness of various monotherapies for alopecia areata (AA),a condition characterized by patchy hair loss. The study, published in the Journal of Cosmetic Dermatology, analyzed data from multiple clinical trials to provide clinicians with a clearer understanding of treatment options.
Key Findings on Treatment Efficacy
The analysis revealed that ritlecitinib, a Janus kinase (JAK) inhibitor, demonstrated superior efficacy compared to other treatments for AA. Specifically, ritlecitinib showed a statistically significant betterment in hair regrowth, with an odds ratio of 2.25 (95% CI, 1.56-3.21, P < .05). This finding suggests that ritlecitinib may be a more effective option for patients seeking considerable hair regrowth. The study also highlighted the efficacy of other JAK inhibitors, including baricitinib adn deuruxolitinib, though their comparative effectiveness relative to ritlecitinib was not explicitly detailed in the provided excerpt. The FDA has approved ritlecitinib at 50 mg once daily, baricitinib at 2 mg and 4 mg once daily, and deuruxolitinib at 8 mg twice daily for the treatment of AA.
Safety profile: No Significant Differences Noted
While the investigators observed some differences in safety profiles among the various therapies,these variations did not reach statistical importance.This suggests that, based on the current data, the overall safety concerns are comparable across the evaluated monotherapies.
Deuruxolitinib’s Market entry and Future Research
Deuruxolitinib, approved last year, faced an initial hurdle due to patent litigation, which led to a court injunction in November. However, the company successfully had the injunction lifted in April, paving the way for the therapy’s launch.The authors of the meta-analysis emphasized that their findings are based on 6-month outcome data.They acknowledged the current limitations in longer-term data and called for future studies to investigate the sustained efficacy and safety of these treatments. Moreover,they advocated for the initiation of actual head-to-head clinical trials. Such trials would provide more robust evidence to guide clinicians in selecting the most effective therapies for individual patients with alopecia areata.
References
- Gupta AK, Bamimore MA, Mirmirani P, Piguet V, Talukder M. The relative efficacy and safety of monotherapies for alopecia areata: a network meta-analysis study. J Cosmet Dermatol. 2025; 24 (4): E70185. doi: 10.1111/play.70185
- Gupta AK, Wang T, Bamimore MA, Piguet V, Tosti A. The relative efficacy of monotherapy with Janus kinase inhibitors,dupilumab and apremilast in adults with alopecia areata: network meta-analyses of clinical trials. J Cosmet Dermatol. 2023; 22 (9): 2553-2559. doi: 10.1111/play.15903
- Guan R, Lin Y, Zhang C, et al. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and contact immunotherapy in the treatment of severe alopecia areata: a systematic review and network meta-analysis. Arch Dermatol Res. 2024; 316 (7): 483. doi: 10.1007/S00403-024-03177-9
- Sun Pharma’s Leqselvi released from patent litigation hold. National Alopecia Areata Foundation. April 11,2025. Accessed July 10, 2025. https://www.naaf.org/news/sun-pharmas-leqselvitm-released-from-patent-litigation-hold/